Profile data is unavailable for this security.
About the company
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
- Revenue in USD (TTM)0.00
- Net income in USD-56.07m
- Incorporated2008
- Employees66.00
- LocationImmuneering Corp245 Main St Fl 2CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 500-8080
- Fax+1 (302) 655-5049
- Websitehttps://immuneering.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Bioqual Inc | 62.86m | 957.02k | 62.61m | 108.00 | 65.42 | 1.61 | 17.85 | 0.996 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Rapt Therapeutics Inc | 0.00 | -120.43m | 63.52m | 122.00 | -- | 0.5816 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
Vor Biopharma Inc | 0.00 | -118.09m | 63.90m | 168.00 | -- | 0.6511 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Gritstone bio Inc | 14.61m | -133.03m | 64.77m | 231.00 | -- | 2.91 | -- | 4.43 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 64.92m | 81.00 | -- | 0.5877 | -- | 2.69 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Maia Biotechnology Inc | 0.00 | -28.08m | 66.94m | 13.00 | -- | 21.02 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
Vivani Medical Inc | 0.00 | -24.20m | 67.41m | 44.00 | -- | 2.83 | -- | -- | -0.4643 | -0.4643 | 0.00 | 0.4316 | 0.00 | -- | -- | 0.00 | -44.89 | -56.58 | -50.97 | -67.66 | -- | -- | -- | -2,868.72 | -- | -- | 0.00 | -- | -- | -- | -84.69 | -- | 40.33 | -- |
Immuneering Corp | 0.00 | -56.07m | 67.61m | 66.00 | -- | 1.02 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -20.60m | 67.98m | 31.00 | -- | 1.77 | -- | -- | -1.43 | -1.43 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -56.37 | -58.43 | -59.43 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Precision BioSciences Inc | 87.64m | 15.79m | 69.44m | 110.00 | -- | 0.9153 | 3.32 | 0.7924 | -0.1363 | 0.202 | 17.59 | 10.49 | 0.5044 | -- | 79.03 | 804,036.70 | 9.09 | -35.35 | 12.24 | -44.22 | -- | -- | 18.02 | -147.50 | -- | -- | 0.2314 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
MDxHealth SA | 80.74m | -40.80m | 70.13m | 300.00 | -- | -- | -- | 0.8686 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
OS Therapies Inc | 0.00 | -6.55m | 70.57m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
Spero Therapeutics Inc | 118.46m | 17.46m | 72.43m | 46.00 | 4.23 | 0.899 | 4.11 | 0.6114 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Tevogen Bio Holdings Inc | 0.00 | 57.92m | 73.82m | 17.00 | 1.15 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Citadel Advisors LLCas of 30 Jun 2024 | 1.88m | 6.35% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.06m | 3.59% |
Millennium Management LLCas of 30 Jun 2024 | 953.23k | 3.22% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 859.37k | 2.90% |
Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 741.55k | 2.50% |
Prosight Management LPas of 30 Jun 2024 | 550.00k | 1.86% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 501.16k | 1.69% |
Marshall Wace LLPas of 30 Jun 2024 | 384.08k | 1.30% |
Renaissance Technologies LLCas of 30 Jun 2024 | 349.10k | 1.18% |
Two Sigma Advisers LPas of 30 Jun 2024 | 248.70k | 0.84% |